Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
7000
¥ million (change in revenue)Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ended March 2023 · Full yearPrevious forecast published 2022年5月11日Net Sales134,000→141,000million
+5.2%
Operating profit27,000→30,000million
+11.1%
Profit attributable to owners of the parent21,500→24,000million
+11.6%
Net income per share319.21→356.33yen
+11.6%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
機能食品事業、ビルテプソ米国売上、国内医薬品などが当初予想を上回る見込みとなったため。
Previous-period results売上収益137,484百万円、営業利益32,948百万円、税引前利益33,301百万円、親会社の所有者に帰属する当期利益24,986百万円、基本的1株当たり当期利益370円97銭（2022年3月期）
Dividend forecast revision中間配当を1株当たり56円から57円に1円増額し、期末配当予想を56円から57円に修正。年間配当予想は112円から114円に2円増額。
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥134,000 million → ¥141,000 million（+5.2%） |
| Operating profit | ¥27,000 million → ¥30,000 million（+11.1%） |
| Profit attributable to owners of the parent | ¥21,500 million → ¥24,000 million（+11.6%） |
| Net income per share | 319.21 yen → 356.33 yen |
| Fiscal Period Covered | Fiscal year ended March 2023 |
| Period Covered | Full year |
| Publication date of previous forecast | 2022年5月11日 |
| Previous-period results | 売上収益137,484百万円、営業利益32,948百万円、税引前利益33,301百万円、親会社の所有者に帰属する当期利益24,986百万円、基本的1株当たり当期利益370円97銭（2022年3月期） |
| Reason for the revision | 機能食品事業、ビルテプソ米国売上、国内医薬品などが当初予想を上回る見込みとなったため。 |
| Dividend forecast revision | 中間配当を1株当たり56円から57円に1円増額し、期末配当予想を56円から57円に修正。年間配当予想は112円から114円に2円増額。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Ordinary incomeDetails and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.機能食品事業、ビルテプソ米国売上、国内医薬品などが当初予想を上回る見込みとなったため。親会社の所有者に帰属する当期利益が当初予想を上回る見込みとなったことから、配当性向35％前後の基本方針に基づき、配当予想も増額した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.